|
【结 构 式】 
|
【分子编号】28459 【品名】methyl (1S,4S,5S,10S)-4-benzyl-1,10-di(tert-butyl)-5-hydroxy-7-[4-[2-(1-methyl-1-phenylethyl)-2H-1,2,3,4-tetraazol-5-yl]benzyl]-2,9,12-trioxo-13-oxa-3,7,8,11-tetraazatetradec-1-ylcarbamate 【CA登记号】 |
【 分 子 式 】C43H59N9O7 【 分 子 量 】813.99792 【元素组成】C 63.45% H 7.31% N 15.49% O 13.76% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(XIII)Deprotection of the Boc group of XI) by treatment with HCl furnished hydrazine (XII), which was coupled with N-methoxycarbonyl-L-tert-leucine (X) to afford bisamide (XIII). The alpha,alpha-dimethyl benzyl protecting group of (XIII) was then removed with 80% H2SO4, and the deprotected tetrazole (XIV) was finally alkylated with CH3I to provide the title compound.
| 【1】 Fassler, A.; Bold, G.; Capraro, H.-G.; Lang, M.; Khanna, S.C. (Novartis AG); Antivirally active heterocyclic azahexane derivs.. EP 0900210; JP 1999511177; US 5849911; WO 9740029 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (X) | 23447 | (2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutyric acid | C8H15NO4 | 详情 | 详情 | |
| (XI) | 28457 | tert-butyl (5S,6S,9S)-6-benzyl-9-(tert-butyl)-5-hydroxy-3-[4-[2-(1-methyl-1-phenylethyl)-2H-1,2,3,4-tetraazol-5-yl]benzyl]-8,11-dioxo-12-oxa-2,3,7,10-tetraazatridecan-1-oate | C40H54N8O6 | 详情 | 详情 | |
| (XII) | 28458 | methyl (1S)-1-([[(1S,2S)-1-benzyl-2-hydroxy-3-(1-[4-[2-(1-methyl-1-phenylethyl)-2H-1,2,3,4-tetraazol-5-yl]benzyl]hydrazino)propyl]amino]carbonyl)-2,2-dimethylpropylcarbamate | C35H46N8O4 | 详情 | 详情 | |
| (XIII) | 28459 | methyl (1S,4S,5S,10S)-4-benzyl-1,10-di(tert-butyl)-5-hydroxy-7-[4-[2-(1-methyl-1-phenylethyl)-2H-1,2,3,4-tetraazol-5-yl]benzyl]-2,9,12-trioxo-13-oxa-3,7,8,11-tetraazatetradec-1-ylcarbamate | C43H59N9O7 | 详情 | 详情 | |
| (XIV) | 28460 | methyl (1S,4S,5S,10S)-4-benzyl-1,10-di(tert-butyl)-5-hydroxy-2,9,12-trioxo-7-[4-(2H-1,2,3,4-tetraazol-5-yl)benzyl]-13-oxa-3,7,8,11-tetraazatetradec-1-ylcarbamate | C34H49N9O7 | 详情 | 详情 |
Extended Information